Christopher S. Boerner
Summary
Christopher S. Boerner has served as Bristol Myers Squibb’s chief executive officer since November 2023 and as board chair since April 2024, after joining the company in 2015. ([bms.com](https://www.bms.com/our-company/leadership/leadership-team/chris-boerner.html?utm_source=openai))
Biography
Boerner is a pharmaceutical executive with experience in commercialization, oncology, immunology and corporate strategy. Before becoming CEO, he was Bristol Myers Squibb’s executive vice president and chief operating officer from April to October 2023 and chief commercialization officer from 2018 to 2023. He previously led the company’s international markets and U.S. commercial markets organizations. ([bms.com](https://www.bms.com/our-company/leadership/leadership-team/chris-boerner.html?utm_source=openai)) Earlier in his career, Boerner held leadership positions at Seattle Genetics from 2010 to 2015 and marketing roles at Genentech from 2002 to 2010. He began his career at McKinsey & Company, advising pharmaceutical and biotechnology clients. Boerner holds a Ph.D. and M.A. in business administration from the University of California, Berkeley, and a bachelor’s degree in economics and history from Washington University in St. Louis. ([bms.com](https://www.bms.com/our-company/leadership/leadership-team/chris-boerner.html?utm_source=openai))
Notable achievements
- Led the commercialization organization behind major BMS franchises before becoming CEO. ([bms.com](https://www.bms.com/our-company/leadership/leadership-team/chris-boerner.html?utm_source=openai))
- Oversaw a business-development push that added Karuna Therapeutics, Mirati Therapeutics and RayzeBio to BMS’s portfolio. ([apnews.com](https://apnews.com/article/bbd1c1e1b4c219fdb822c6755fc1dd79?utm_source=openai))
- BMS launched Cobenfy for schizophrenia during his tenure and expanded approvals for products including Breyanzi, Reblozyl and Opdivo. ([sec.gov](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm?utm_source=openai))
- Under his leadership, BMS reported $48.2 billion in 2025 revenue, with growth products including Opdivo, Breyanzi and Cobenfy contributing to the portfolio. ([bms.com](https://www.bms.com/investors/financial-reporting/key-facts.html?utm_source=openai))
Problem areas / controversies
- The acquisition program created substantial near-term costs; BMS reported a large first-quarter 2024 loss that included charges associated with the transactions. ([statnews.com](https://www.statnews.com/2024/04/25/bristol-myers-squibb-ceo-christopher-boerner-future-plans/?utm_source=openai))
- BMS remains exposed to a patent-cliff challenge because Eliquis and Opdivo are expected to face major U.S. exclusivity pressure around 2028. ([sec.gov](https://www.sec.gov/Archives/edgar/data/14272/000001427225000039/bmy-20241231.htm?utm_source=openai))
- The company has pursued workforce reductions and cost savings while trying to fund pipeline development, creating execution and employee-relations challenges. ([fortune.com](https://fortune.com/article/bristol-myers-squibb-ceo-chris-boerner-patent-cliff-company-culture/?utm_source=openai))
- No major personal regulatory or ethics controversy involving Boerner was identified in the reviewed public filings and reputable coverage.